Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TCF4 | P15884 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | GLA | P06280 | 4/20 | 0.56 |
| ▸ | GFER | P55789 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663530 | 0.88 | MEN1 (0.77) | TCF4CTNNB1MEN1KMT2ARXFP1 | |
| SCHEMBL13836671 | 0.88 | TCF4 (0.64) | TCF4CTNNB1NPC1KDM4EMAPT | |
| SCHEMBL30533210 | 0.87 | MEN1 (0.73) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| SCHEMBL1655753 | 0.87 | MEN1 (0.73) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| SCHEMBL28312335 | 0.86 | ALDH1A1 (0.74) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| SCHEMBL8769051 | 0.86 | MEN1 (0.71) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| SCHEMBL159873 | 0.86 | ALDH1A1 (0.74) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| SCHEMBL30307784 | 0.86 | ALDH1A1 (0.74) | MEN1KMT2ARXFP1CACNA1BAPBA1 | |
| SCHEMBL31289475 | 0.86 | MEN1 (0.55) | TCF4CTNNB1MEN1KMT2ARXFP1 | |
| SCHEMBL29002248 | 0.84 | SIRT2 (0.53) | TCF4CTNNB1MEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733300-A1 | NOVEL CHROMENE-BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024263007-A1 | NOVEL CHROMENE-BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-12-26 | — | — | WO | disclosed |
| WO-2024219864-A1 | NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF | 주식회사 넷타겟 | 2024-10-24 | — | — | WO | disclosed |
| EP-4198025-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF INFECTIOUS DISEASES | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2023-06-21 | — | — | EP | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-103282034-A | Use of hematopoietic growth factor mimetics | LIGAND PHARM INC | 2013-09-04 | — | — | CN | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| CN-102656141-A | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | TCF4 1470/4885CTNNB1 4056/4885MEN1 1370/4885 |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | TCF4 1183/4885CTNNB1 2581/4885MEN1 1395/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | TCF4 1183/4885CTNNB1 2581/4885MEN1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.